The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy
Abstract
It has become apparent that the clinical success anticipated in the field of gene therapy has been limited by progress in several of the fundamental areas of genetics, molecular and cellular biology relevant to its application. Whilst a great deal of effort has been made in the evaluation of transgenes, it is only more recently with the advance of vector systems that attention has begun to be focused upon the means and control of transgene expression. Until recently, the majority of constructs have employed ubiquitous viral promoters to drive expression from simple gene expression cassettes using viral promoters and lacking introns, 3' untranslated regions (UTRs), locus control regions (LCR's), matrix attachment regions (MAR's) and other such genetic components. It has consequently emerged that these elements may have a key role in determining the levels and longevity of gene expression attainable in vivo, irrespective of the vector system utilised. The majority of gene therapy applications would also benefit from the specific optimisation of 'tailor-made' expression cassettes to optimise their therapeutic efficacy. In conjunction with modification of vector tropism and strategies to limit their immunogenicity, this should create vectors suitable for the clinical application of gene therapy. This review aims to highlight some of the principle considerations of gene expression in vivo, and the means by which it may most effectively be achieved, whether this is via the minimal modification of an existing eukaryotic promoter or by the more extensive design of a novel promoter and associated elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 1×
“…system, which is based on the highlysensitive prokaryotic tetracycline resistance operon and has demonstrated a highly suitable kinetic and dose-response profile in numerous studies in vitro and in vivo [Blau et al., 1999; Gossen et al., 1995; Rossi et al., 1998; Urlinger et al., 2000] (see Fig.”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
The enhanceosome and transcriptional synergy.
Carey, M. (1998) · Cell · doi:10.1016/s0092-8674(00)80893-4 · Cited by 553
Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element
Donello, J. E., Loeb, J. E., & Hope, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5085-5092.1998 · Cited by 350
Loeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., & Hope, T. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950016942 · Cited by 279
Enhancer–promoter specificity mediated by DPE or TATA core promoter motifs
Butler, J. E. F., & Kadonaga, J. T. (2001) · Genes & Development · doi:10.1101/gad.924301 · Cited by 265
Gill, D., Smyth, S., Goddard, C., Pringle, I., Higgins, C., Colledge, W., & Hyde, S. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301561 · Cited by 214
Xu, R., Janson, C., Mastakov, M., Lawlor, P., Young, D., Mouravlev, A., Fitzsimons, H., Choi, K.-L., Ma, H., Dragunow, M., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301529 · Cited by 174
Cordier, L., Gao, G.-P., Hack, A. A., McNally, E. M., Wilson, J. M., Chirmule, N., & Sweeney, H. L. (2001) · Human Gene Therapy · doi:10.1089/104303401750061267 · Cited by 152
Chen, H., McCarty, D., Bruce, A., Suzuki, K., & Suzuki, K. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300547 · Cited by 87 · cited 1×
“Target tissue Promoter Vector Transgene References Prolactin Ad LacZ, HSV-tk [Southgate et al., 2000] Myelin basic protein AAV GFP [Chen et al., 1998] Ankyrin Retrovirus Lentivirus γ-globin ferrochelatase [Sabatino et al., 2001] [Richard et al., 2001] α-spectrin, Globin Lentivirus GFP, β/γ -globin…”
Background
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
mRNA-Based Protein Replacement Therapy for the Heart
Magadum, A., Kaur, K., & Zangi, L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.018 · Cited by 176
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
Methods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
Joglekar, A. V., Hollis, R. P., Kuftinec, G., Senadheera, S., Chan, R., & Kohn, D. B. (2013) · Molecular Therapy · doi:10.1038/mt.2013.106 · Cited by 65
Metadata
- Authors
- Papadakis, E., Nicklin, S., Baker, A., & White, S.
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-03-01
- Volume
- 4
- Issue
- 1
- Pages
- 89-113
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W2108620620
- Cited by
- 170
- References
- 10
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy. https://app.cochat.ai/papers/10.2174/1566523044578077
- The paper
- Papadakis, E., Nicklin, S., Baker, A., & White, S. (2004). Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy. Current Gene Therapy. https://doi.org/10.2174/1566523044578077
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.